CKPT Overview

Key Data

  • Open $2.6900
  • Day Range 2.5500 - 2.7300
  • 52 Week Range 1.5580 - 5.3762
  • Market Cap $210.63M
  • Shares Outstanding 72.18M
  • Public Float 60.24M
  • Beta 1.24
  • Rev. per Employee $106.90K
  • P/E Ratio N/A
  • EPS -$0.4169
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 3.04M 05/14/21
  • % of Float Shorted 5.04%
  • Average Volume 852.58K

Performance

5 Day
  • 1.53%
1 Month
  • 10.83%
3 Month
  • -16.88%
YTD
  • 0.38%
1 Year
  • 24.30%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Checkpoint Therapeutics started at buy with $18 stock price target at B. Riley

Jun. 9, 2021 at 8:21 a.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

Colonial Pipeline Cyberattack Puts All Eyes on FireEye

May. 12, 2021 at 4:53 p.m. ET on InvestorPlace.com

Analysts Offer Insights on Healthcare Companies: Checkpoint Therapeutics (CKPT) and Sensei Biotherapeutics (SNSE)

May. 12, 2021 at 11:25 a.m. ET on SmarterAnalyst

7 Penny Stocks That May Have Room to Run Higher

Mar. 31, 2021 at 7:55 a.m. ET on InvestorPlace.com

Checkpoint Therapeutics (CKPT) Receives a Buy from H.C. Wainwright

Mar. 15, 2021 at 6:16 a.m. ET on SmarterAnalyst

These 2 Penny Stocks Could Rack up Triple-Digit Gains, Say Analysts

Feb. 11, 2021 at 11:16 a.m. ET on TipRanks.com

Checkpoint Therapeutics (CKPT) Gets a Buy Rating from H.C. Wainwright

Nov. 9, 2020 at 11:45 a.m. ET on SmarterAnalyst

Top Analyst Upgrades and Downgrades: AbbVie, CSX, Dominion, JPMorgan, NXP, ONEOK, Pfizer, Square, UPS, ViaSat, WPX Energy and More

Sep. 29, 2020 at 9:05 a.m. ET on 247WallSt.com

Checkpoint Therapeutics Inc.

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in New York, NY.

Competitors

Name Chg % Market Cap
Ono Pharmaceutical Co. Ltd. ADR 1.66% $11.05B
Oncolix Inc. -90.00% $512.26
Omeros Corp. -1.31% $1B
Competitor Data Provided ByCapital Cube Logo